pharmaphorum

AUGUST 17, 2020

In this article Joanna Carlish, managing director of financial services at Tag Americas , and Robb DeFilippis, Tag Americas’ managing director, life sciences, go head-to-head to discuss marketing within a regulated industry. Personalising marketing content. Virtual connections. Regulated industry learnings.

Communication 97

Communication Insurance Packaging Pharmaceutical Companies 97

pharmaphorum

JULY 23, 2019

Companies like Apple and Amazon have elevated customer expectations for personalised content and interactions across multiple channels, in the process setting new standards for marketing. But, as they push the envelope, what are the implications for pharma’s work in customer engagement?

Pharmaceutical Companies 52

Pharmaceutical Companies Pharmaceutical Companies 52

Pharmaceutical Technology

MAY 2, 2023

The unmet needs can be grouped into the broad categories of efficacy-related needs, cost-related needs, toxicity-related needs, personalised care-related needs, and “other” needs. IO therapies come with a hefty price tag, with ICI therapies in the US typically exceeding $100,000, while cell therapies can exceed $400,000.

Immunization 52

Immunization Vaccines 52

pharmaphorum

SEPTEMBER 15, 2020

This gives them huge amounts of customer data that allows them to shape and personalise the way they engage with their customers, not least thanks to the direct-to-consumer sales model they often offer. Jeremy Richter, Tag. Joe adds: “Digitally-native brands also have a laser focus on the channels they’re executing for.

Communication 129

Communication Documentation Labelling Vaccines 129

pharmaphorum

MAY 24, 2021

Modular content is an established practice among digital and content marketers in sectors such as FMCG and retail, who are challenged with increasing demand for more content and creating personalised content to meet the demands of their customers. The post What is modular content and why do pharma marketers need it NOW?

Communication 101

Communication Packaging Pharmaceutical Companies Pharmaceutical Companies 101

pharmaphorum

JUNE 15, 2021

The adoption of New Science – a unique combination of the best in science and health technology that address significant unmet patient needs – is delivering more precise and effective treatments, but often at a higher price tag, according to new research. billion and $6.7 People simply can’t afford them. But there is a silver lining.

Vaccines 89

Vaccines 89